These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Evaluation of the Efficacy and Safety of the New Susanna Glaucoma Drainage Device in Refractory Glaucomas: Short-term Results.
    Author: Biteli LG, Prata TS, Gracitelli CP, Kanadani FN, Villas Boas F, Hatanaka M, Paranhos Junior A.
    Journal: J Glaucoma; 2017 Apr; 26(4):356-360. PubMed ID: 28118203.
    Abstract:
    PURPOSE: To assess the efficacy and safety of the new Susanna glaucoma drainage device (SGDD) in patients with neovascular and refractory glaucomas. MATERIALS AND METHODS: In this prospective study, patients with neovascular glaucoma or refractory glaucomas (defined as eyes with previous trabeculectomy failure) were enrolled. All eyes had to have intraocular pressure (IOP) above 21 mm Hg despite maximum tolerated topical medication, or recent documentation of anatomic and/or functional progression. Patients underwent glaucoma surgery with the new SGDD in a standardized manner. Postoperative visits were performed at days 1 and 7; months 1, 3, and 6; and every 6 months thereafter. Preoperative and postoperative IOP, number of antiglaucoma medications, surgical complications, and any subsequent related events were recorded. Success criteria were: (I) IOP≥6 and ≤21 mm Hg; (II) IOP≥6 and ≤18 mm Hg. Each criterion was classified as complete (without medication) or qualified (with medication). RESULTS: A total of 58 patients with a mean age of 64.3±11.5 years were included [19 with neovascular glaucoma (group 1) and 39 with failure of first trabeculectomy (group 2)]. Overall, mean follow-up was 7.1±3.8 months, and mean IOP was reduced from 31.5±1.6 (range, 18 to 68) mm Hg to 12.6±0.7 (range, 2 to 28) mm Hg at the last follow-up visit (P<0.01). The mean number of antiglaucoma medications used was reduced from 3.4±0.9 to 1.4±1.5 (P<0.01). At 6 months postoperatively, qualified success rates for groups 1 and 2 were 73% and 86%, respectively (considering the stricter criterion). Main complications were 2 cases of conjunctival erosion and 2 cases of late hypotony. CONCLUSIONS: Our initial findings suggest that the new SGDD is an effective alternative for managing neovascular and refractory glaucomas, with minor postoperative complications in the short-term.
    [Abstract] [Full Text] [Related] [New Search]